Back to results
US 10,246,749 B2Granted
Method for diagnosing breast cancer
AssigneeAlbert-Ludwigs-Universitaet Freiburg
InventorsElmar Stickeler, Thalia Erbes, Markus Jaeger
Life of this patent
Estimating the term…
Abstract
The invention relates to a method of diagnosing breast cancer and to the use of biomarkers for the detection and diagnosis of breast cancer.
Claims16
A method of diagnosing a subject with breast cancer, said method comprising the steps of:
- a. detecting and measuring the levels of the following four miR gene products:
- miR-21, miR125b, miR-451, and miR-155 in a cell-free test sample isolated from a whole urine sample obtained from said subject;
- b. comparing the respective levels of each of said four miR gene products in the subject test sample detected and measured in step (a) with its corresponding miR gene product control level in a control sample;
- and
- c. diagnosing with breast cancer the subject for whom the comparison of step (b) reveals a decrease in the respective levels of miR-21, miR-125b, and miR-451, and an increase in the level of miR-155 in the subject test sample measured in step (a) as compared to each corresponding control level,
- wherein said cell-free test sample is a supernatant isolated from the whole urine sample, wherein the whole urine sample has been processed to eradicate contamination with any urothelial or microbiological cell material.
3 more elements
A method of treating breast cancer in a subject in need thereof, said method comprising the steps of:
- a. in a cell free test sample isolated from a whole urine sample obtained from the subject, detecting and measuring the respective levels of the following four miR gene products:
- miR-21, miR-125b, miR-451, and miR-155;
- b. comparing the levels of each of said four miR gene products in the subject test sample measured in step (a) with its corresponding miR gene product control level in a control sample;
- and
- c. administering a chemotherapeutic regimen suitable for treating breast cancer to the subject for whom the comparison of step (b) reveals a decrease in the level of the miR-21 gene product, the miR-125b gene product, and the miR-451 gene product in the subject test sample, relative to the corresponding control level for the respective gene product(s) and reveals an increase in the level of the miR-155 gene product in the subject test sample, relative to the corresponding control level for the respective gene product(s),
- wherein said cell-free test sample is a supernatant isolated from the whole urine sample, wherein the whole urine sample has been processed to eradicate contamination with any urothelial or microbiological cell material.
3 more elements
Dependencies are inferred from the claim text.